Tri-weekly Docetaxel Versus Bi-weekly Docetaxel as a Treatment for Advanced Castration Resistant Prostate Cancer: Quality of Life Analysis
Administering chemotherapy using docetaxel (taxotere or T) on a bi-weekly basis with prednisone improved progression free survival and overall survival when compared with the standard tri-weekly schedule for men with advanced castration resistant prostate cancer [...]
Identifying Men at Greatest Risk of Weight Gain from Androgen Deprivation Therapy
Androgen Deprivation Therapy (ADT) or Hormone Therapy (HT) to treat prostate cancer is a mainstay of therapy for men with recurrent or metastatic disease. There are many side effects associated with ADT including weight gain. [...]
Application for the FDA Approval of Xtandi in the Pre-Chemo State Has Finally been Submitted
The good news is that finally Astellas and Medivation have submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of XTANDI (enzalutamide) for the treatment of men [...]
Toxicity Analysis of Lymph Node Irradiation for Men with Prostate Cancer Treated with IMRT
The standard of treatment for men who have a localized recurrence in lymph nodes (LN) after surgery is intensity modulated radiation therapy (IMRT) as well as with men who have high-risk prostate cancer which includes [...]
More Issues Raised About Cross-Resistance Between Abiraterone and Enzalutamide
Some of my posts over the last week or two have discussed the issue of the development of cross-resistance of two of our newest treatments for advanced prostate cancer. These drugs are abiraterone (Zytiga) and [...]
Markers for Predicting Clinical Responses to Sipuleucel-T (Provenge) in Castrate Resistant Prostate Cancer
Sipuleucel-T (Provenge) has shown in clinical trials that it prolongs overall survival (OS) in asymptomatic or minimally symptomatic men with castrate resistant prostate cancer (CRPC). Unlike many other treatments for men with CRPC there are [...]